Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001628280-25-034814
Filing Date
2025-07-11
Accepted
2025-07-11 17:46:19
Documents
1
Period of Report
2025-06-02

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1752270372.html 4  
1 FORM 4 wk-form4_1752270372.xml 4 32091
  Complete submission text file 0001628280-25-034814.txt   33513
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Issuer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 2525 WEST END AVENUE, SUITE 950 NASHVILLE TN 37203
Business Address
Krogulski Kenneth (Reporting) CIK: 0001695580 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33637 | Film No.: 251119816